Results 281 to 290 of about 276,787 (297)

Cohort profile: Cell-omics Resource of the Australian Genetics of Depression Study (AGDS:Cell-o)

Mitchell B, Gilroy D, Wallace L, Kiewa J, Parker R, Nunn L, Walker A, Lin T, Ziser L, English G, O’Neill M, Pertile R, McKenna S, Hockey S, Hill A, Shim A, To T, Treneman A, McIntosh A, Crouse J, Lind P, Medland S, Martin N, Hickie I, Henders A, Wray N.   +25 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antidepressant‐induced sexual dysfunction

Medical Journal of Australia, 2020
Sexual dysfunction is a frequent, potentially distressing, adverse effect of antidepressants and a leading cause of medication non‐adherence. Sexual function should be actively assessed at baseline, at regular intervals during treatment, and after ...
Jody Rothmore
semanticscholar   +1 more source

Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.

New England Journal of Medicine, 2019
Esketamine for Treatment-Resistant Depression The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression.
Jean Kim, Tiffany R. Farchione, Andrew Potter, Qi Chen, R. Temple   +4 more
semanticscholar   +1 more source

Depression: a new animal model sensitive to antidepressant treatments

Nature, 1977
R. Porsolt, M. Pichon, M. Jalfre
semanticscholar   +1 more source

Antidepressant effects of ketamine in depressed patients

Biological Psychiatry, 2000
R. Berman, A. Cappiello, A. Anand, D. Oren, G. Heninger, D. Charney, J. Krystal   +6 more
semanticscholar   +1 more source